{"id":"NCT00975715","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures","officialTitle":"A Multicentre, Randomized, Double-blind, Placebo Controlled, Parallel-group Study in Children With Inadequately Controlled Partial Onset Seizures to Investigate Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) as Adjunctive Therapy","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2009-09","primaryCompletion":"2012-10","completion":"2012-10","firstPosted":"2009-09-11","resultsPosted":"2014-01-24","lastUpdate":"2014-07-16"},"enrollment":99,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Partial Onset Seizures"],"interventions":[{"type":"DRUG","name":"TRI476","otherNames":[]},{"type":"DRUG","name":"Placebo to TRI476","otherNames":[]},{"type":"DRUG","name":"Benzodiazepines","otherNames":[]}],"arms":[{"label":"TRI476","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study is designed to provide short term efficacy and safety data of TRI476 in children with inadequately-controlled partial seizures. Patients will be randomized into either drug treatment or placebo group at 1:1 ratio, and receive their respective treatment for 8 weeks. The purpose of study is to confirm that TRI476 as adjunctive therapy is effective and safe.","primaryOutcome":{"measure":"Percent Change in Partial Onset Seizure Frequency Per 28 Days From Baseline to the Double-blind Phase, by Treatment Group","timeFrame":"screening and 28 days","effectByArm":[{"arm":"TRI476","deltaMin":-2.85,"sd":63.546},{"arm":"Placebo","deltaMin":14.82,"sd":73.333}],"pValues":[]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":25,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["http://www.novartisclinicaltrials.com/webapp/etrials/home.do"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":47},"commonTop":["Somnolence","Nasopharyngitis","Upper respiratory tract infection","Vomiting","Rash"]}}